Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of CTx-1301 in Healthy Adults
NCT04449250Phase 1Completed
- Sponsor
- Cingulate Inc.
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexmethylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Cingulate Inc. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 1 more. Started Sep 2022; status: completed.
02
Drugs
dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04449250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449250.